期刊文献+

硼替佐米治疗肾功能不全多发性骨髓瘤患者疗效观察 被引量:4

下载PDF
导出
摘要 目的:探讨硼替佐米治疗肾功能不全多发性骨髓瘤(MM)患者的疗效及安全性。方法:肾功能正常的MM患者11例,为对照组;肾功能不全的MM患者8例,为观察组。均接受硼替佐米为主的方案化疗。观察、记录化疗前后肾功能的变化、化疗效果、不良反应。结果:①8例观察组患者7例呈现疗效反应,有效率87.50%;11例对照组患者9例呈现疗效反应,有效率81.82%,两组比较差异无统计学意义(P>0.05);两组患者治疗后β2-微球蛋白均明显下降(P<0.05);②肾功能不全患者化疗前血清肌酐为(316.75±162.09)μmol/L,化疗后为(179.25±112.59)μmol/L,较化疗前显著下降(P<0.01);8例肾功能不全患者硼替佐米化疗后,有5例获得肾功能逆转,1例肾功能好转,无1例患者出现肾功能恶化情况,肾功能改善率达75%;③不良反应:以消化道反应、1~2级血液学毒性为主,少数患者有较轻的神经损害症状,这些不良反应两组无显著差异。结论:对肾功能不全MM患者,硼替佐米为主的治疗方案兼顾疗效和安全性,并多能实现肾功能逆转,可作为一线治疗方案选择。
作者 徐敏 郭宗明
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2013年第4期525-527,共3页 Journal of Nanjing Medical University(Natural Sciences)
  • 相关文献

参考文献7

  • 1Durie BG,Harousseau JL,Miguel JS,et al. International Myeloma Working Group:international uniform response criteria for multiple myeloma[ J ]. Leukemia, 2006,20 (9) : 1467-1473.
  • 2Pineda-Roman M,Zangari M,van Rhee F,et al. VTD eom- bina-tion therapy with bortezomib-thalidomide-dexametha- sone ishighly effective in advanced and refractory multiple myeloma[J]. Leukemia,2008,22(7): 1419-1427.
  • 3Chanan-Khan AA,Kaufman JL,Mehta J,et al. Activity and safety of bortezomib in multiple myeloma patients with ad- vanced renal failure : a multicenter retrospective study [J]. Blood. 2007,109(6) : 2604-2606.
  • 4周桥,卢颖,仲芳,郝旭,李聪,郭山脉,王伟铭,陈楠.蛋白酶体抑制剂硼替佐米对阿霉素肾病大鼠肾脏的保护作用[J].上海交通大学学报(医学版),2011,31(2):158-164. 被引量:7
  • 5Tashiro K,Tamada S,Kuwabara N,et al. Attenuation of renal fibrosis by proteasome inhibition in rat obstructive nephropathy:possible role of nuclear factor kappaB [J]. Int J Mol Med,2003,12(4):587-592.
  • 6Mitch WE. Proteolytic mechanisms,not malnutrition,cause loss of muscle mass in kidney failure [J]. J Ren Nutr, 2006,16(3) :208-211.
  • 7Chade AR,Herrmann J,Zhu X,et al. Effects of protea- some inhibition on the kidney in experimental hyperc- holesterolemia [J]. J Am Soc Nephrol,2005,16 (4): 1005-1012.

二级参考文献23

  • 1马立彬,刘丽蓉,刘晓城,徐钢,曾锐,何晓峰,刘蔚.MG132对TGF-β1诱导的人肾小管上皮细胞Smad泛素化调节因子2和Smad7的影响[J].中华肾脏病杂志,2006,22(12):771-772. 被引量:8
  • 2Mihailovic-Stanojevic N,Jovovic D,Miloradovic Z,et al.Reducedprogression of adriamycin nephropathy in spontaneously hypertensiverats treated by losartan. Nephrology Dialysis Transplantation . 2008
  • 3Nagashima A,Okuda S,Tamaki K,et al.Influence of a high saltdiet on glomerular injury and the preventive effects of amiloride inadriamycin nephropathy. Nephron . 1995
  • 4Cavaletti G,Gilardini A,Canta A,et al.Bortezomib-inducedperipheral neurotoxicity:a neurophysiological and pathological studyin the rat. Experimental Neurology . 2007
  • 5Bardag-Gorce F,Oliva J,Lin A,et al.Proteasome inhibitor upregulates liver antioxidative enzymes in rat model of alcoholic liverdisease. Experimental and Molecular Pathology . 2011
  • 6Li Y,Kang YS,Dai C,et al.Epithelial-to-mesenchymal transitionis a potential pathway leading to podocyte dysfunction and proteinuria. American Journal of Pathology . 2008
  • 7Kang YS,Li Y,Dai C,et al.Inhibition of integrin-linked kinaseblocks podocyte epithelial-mesenchymal transition and amelioratesproteinuria. Kidney International . 2010
  • 8Wagner-Ballon O,Pisani DF,Gastinne T,et al.Prteasome inhibi-tor bortezomib impairs both myelofibrosis and osteosclerosis inducedby high thrombopoietin levels in mice. Blood . 2007
  • 9Okuda S,Oh Y,Tsuruda H,et al.Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney International . 1986
  • 10Meiners S,Dreger H,Fechner M,et al.Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Journal of Hypertension . 2008

共引文献6

同被引文献17

  • 1李剑,许莹,李航,沈悌.多发性骨髓瘤合并肾功能不全38例临床和预后分析[J].中国实用内科杂志,2006,26(3):341-343. 被引量:15
  • 2Richardson PG,Barlogie B,Berenson J,et al. A phase 2 study of bortezomib in relapsed,refractory myeloma[J]. N Engl J Med, 2003,348 (26) : 2609-2617.
  • 3Durie BG,Harousseau JL,Miguel JS,et al. International Myeloma Working Group:international uniform response criteria for mnl-tiple myeloma [J]. Leukemia,2006,20 (9) : 1467-1473.
  • 4Reeder CB,Reece DE, Kukreti V,et al. Cyclophosphamide bortezomib and dexamethasone induction for newly diag- nosed multiple myeloma:high response rates in a phase Ⅱ clinical trial[J]. Leukemia,2009,23(7) : 1337-1341.
  • 5Hideshima T, Miltiades C,Akiyama M,et al. Molecular mechanisms mediating antimyeloma activity of protea- some inhibitor PS-341 [J]. Blood,2003,101 (4) : 1530- 1534.
  • 6Jullig M,Zhang WV,Ferreira A,et al. MG132 induced apoptosis is associated with P53-independent induction of pro-apoptotic NOXA and transcriptional activity of beta- catenin[J]. Apoptosis, 2006,11 (4) : 627-641.
  • 7Roccaro AM,Hideshima T,Raje N,et al. Bortezomib me- diates antiangi ogenesis in multiple myeloma via direct and indirect effects on endothelial cells [J]. Cancer Ras, 2006,66(1):184-191.
  • 8Richardson PG,Barlogie B,Berenson J,et al.A phase 2 study of bortezomib in relapsed,refractory myeloma[J].N Engl J Med,2003, 348(26):2609-2617.
  • 9Durie BG,Harousseau JL,Miguel JS,et al.International Myeloma Working Group:international uniform response criteria for multiple myeloma[J] .Leukemia,2006,20(9): 1467-1473.
  • 10李菁媛,谢红,冉启杰,周敏,王军,张新华.小剂量硼替佐米联合地塞米松治疗复发难治性多发性骨髓瘤的疗效[J].临床内科杂志,2011,28(3):201-202. 被引量:4

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部